Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid-and long-term prediction of hepatocellular carcinoma among cirrhotic patients

BACKGROUND The combination of alpha-fetoprotein(AFP)and squamous cell carcinoma antigen immunocomplex(SCCA-IgM)have been proposed for its use in the screening of hepatocellular carcinoma(HCC).Current screening programs for all cirrhotic patients are controversial and a personalized screening is an unmet need in the precision medicine era.AIM To determine the role of the combination of SCCA-IgM and AFP in predicting mid-and long-term appearance of HCC.METHODS Two-hundred and three cirrhotic patients(Child A 74.9%,B 21.2%,C 3.9%)were followed-up prospectively every six months to screen HCC by ultrasound and AFP according to European Association for the Study of the Liver guidelines.The estimation cohort was recruited in Italy(30.5%;62/203)and validation cohort from Spain(69.5%;141/203).Patients underwent to evaluate SCCA-IgM by enzyme-linked immunosorbent assay(Hepa-IC,Xeptagen,Italy)and AFP levels at baseline.Patients were followed-up for 60 mo,being censored at the time of the appearance of HCC.RESULTS There were 10.8%and 23.1%of HCC development at two-and five-years followup.Patients with HCC showed higher levels of SCCA-IgM than those without it(425.72±568.33 AU/mL vs 195.93±188.40 AU/mL,P=0.009)during the fiveyear follow-up.In multivariate analysis,after adjusting by age,sex,aspartate transaminase and Child-Pugh,the following factors were independently associated with HCC:SCCA-IgM[Hazard ratio(HR)=1.001,95%CI:1.000-1.002;P=0.003],AFP(HR=1.028,95%CI:1.009-1.046;P=0.003)and creatinine(HR=1.56495%CI:1.151-2.124;P=0.004).The log-rank test of the combination resulted in 7.488(P=0.024)in estimation cohort and 11.061(P=0.004)in the validation cohort,and a 100%of correctly classified rate identifying a low-risk group in both cohorts in the two-year follow-up.CONCLUSION We have constructed a predictive model based on the combination of SCCA-IgM and AFP that provides a new HCC screening method,which could be followed by tailored HCC surveillance for individual patients,especially for those cirrhotic patients belonging to the subgroup identified as low-risk of HCC development.

High expression of squamous cell carcinoma antigen in poorly differentiated adenocarcinoma of the stomach: A case report

BACKGROUND Squamous cell carcinoma antigen(SCCA)is regarded as a specific indicator of epithelial malignancies and is widely used in the diagnosis of squamous cell carcinoma(SCC).However,the expression of SCCA in gastric adenocarcinoma has not been studied in detail.CASE SUMMARY A 52-year-old man was admitted to our hospital for a 2.5 cm x 2.5 cm ulcer at the antrum-body junction with dull pain and fullness in the upper abdomen for 2 mo.His pre-surgery serological testing results showed 0.51 ng/mL SCCA(reference interval,<1.5 ng/mL)and 9.9 ng/mL carcinoembryonic antigen(reference range,<4.7 ng/mL).He underwent radical distal gastrectomy and Roux-en Y anastomosis and was diagnosed with poorly differentiated mucinous adenocarcinoma(Lauren classification:Diffuse)by pathological examination of the resected lesion.Immunohistochemistry showed that SCCA was highly expressed in the cytoplasm of cancer cells.After surgery,the patient received an S-1 adjuvant chemotherapy regimen for six cycles containing tegafur,gimeracil,and oteracil potassium.He showed no sign of recurrence or metastasis within 24-mo follow-up.CONCLUSION This is a frontal report of SCCA overexpression in poorly differentiated adenocarcinoma of the stomach.

Clinical applications of squamous cell carcinoma antigenimmunoglobulins M to monitor chronic hepatitis C

Hepatitis C virus(HCV) is the main cause of chronic liver disease and cirrhosis in Western countries. Over time, the majority of cirrhotic patients develop hepatocellular carcinoma(HCC), one of the most common fatal cancers worldwide- fourth for incidence rate. A high public health priority need is the development of biomarkers to screen for liver disease progression and for early diagnosis of HCC development, particularly in the high risk population represented by HCV-positive patients with cirrhosis. Several studies have shown that serological determination of a novel biomarker, squamous cell carcinoma antigen-immunoglobulins M(SCCA-Ig M), might be useful to identify patients with progressive liver disease. In the initial part of this review we summarize the main clinical studies that have investigated this new circulating biomarker on HCV-infected patients, providing evidence that in chronic hepatitis C SCCA-Ig M may be used to monitor progression of liver disease, and also to assess the virological response to antiviral treatment. In the last part of this review we address other, not less important, clinical applications of this biomarker in hepatology.

Identification of interleukin-6 (IL-6) and squamous cell carcinoma (SCC) as amniotic fluid-specific markers

Objective: To determine if an amniotic fluid (AF)-specific marker is present and if its concentration changes with the presence of labor. Study Design: Twenty-six healthy women who gave birth to healthy newborns at term during the period from July 2009 to January 2010 were included in the study. Six candidate markers were assessed by commercially available ELISA kits: interleukin (IL)-6, squamous cell carcinoma (SCC) antigen, insulin-like growth factor (IGFBP)-1, osteopontin (OPN), CA125, and sialyl Tn (STN). Results: The AF/maternal serum (MS) measurement based on IL-6 or SCC has proved to be superior to IGFBP-1, CA125, OPN and STN. Women with spontaneous labor at term had significantly higher IL-6 and IGFBP-1 concentrations in AF compared with those without labor. No significant differences were observed in the AF concentrations of SCC, OPN, CA125 and STN between women with labor and those not in labor. Conclusion: Our observation of IL-6 and SCC in AF may open a new area of research to assess their usefulness as biological markers of obstetrical disorders.

Predicting malignant transformation of esophageal squamous cell lesions by combined biomarkers in an endoscopic screening program

AIM To determine the association of p53, carcinoembryonic antigen(CEA) and CA19-9 protein expression with esophageal carcinogenesis.METHODS An iodine staining endoscopic screening program of esophageal lesions was carried out in the high-incidence area of Feicheng County, China. Seventy-seven patients with basal cell hyperplasia(BCH), 247 with low-grade dysplasia(LGD), 51 with high-grade dysplasia(HGD), 134 with invasive cancer, and 80 normal controls diagnosed by mucous membrane biopsy pathology were enrolled. Immunohistochemical detection of p53, CEA and CA19-9 proteins was performed. In the ROCcurve analysis, the expression of a single biomarker and the expression of a combination of biomarkers were used to predict the risk of these four esophageal lesions.RESULTS The positive rates of p53 protein expression in invasive cancer, HGD, LGD, BCH and the normal control groups were 53.0%, 52.9%, 35.6%, 27.3% and 20.0%, respectively; the positive rates of CA19-9 protein expression were 44.0%, 33.3%, 16.5%, 9.2% and 6.2%, respectively; the positive rates of CEA protein expression were 74.6%, 60.8%, 23.3%, 23.7% and 16.2%, respectively. The positive rates of the combined expression of the three biomarkers were 84.3%, 76.5%, 47.6%, 42.9% and 27.5%, respectively. In the receiver operating characteristic curves of the combination of the three biomarkers, the specificity was 88.8% for the normal controls, and the sensitivity was 58.2% for invasive cancer, 25.5% for HGD, 11.2% for LGD, and 6.5% for BCH.CONCLUSION p53, CEA and CA19-9 protein expression was correlated with esophageal carcinogenesis, and testing for the combination of these biomarkers is useful for identifying high-risk patients with precancerous lesions.

The expression and the clinical significance of eukaryotic translation initiation factors 4E and p53 in squamous cell carcinoma

Objective： To study the expression of eukaryotic initiation factor-4E （eIF-4E） and p53 in squamous cell carcinomas （SCC） and to explore their relationship and clinical significance. Methods： The expression of elF-4E and p53 in 32 cases of SCC was detected by immunohistochemical SABC method. Results： The positive rate of elF-4E and p53 expression was 93.8% and 56.3% in SCC, and the levels of eIF-4E and p53 were significantly higher in SCC than those in the normal skin tissue （P 〈 0.05）. Conclusion： Both elF-4E and p53 were useful markers in SCC, but the specialty and sensitivity of the eiF- 4E protein was high in SCC.

Impact of Preoperative Serum Tumor Markers in Patients with Lung Squamous Cell Carcinoma

Background: Several previous researchers have investigated the prognostic value of serum tumor markers, especially carcinoembryonic antigen (CEA). Only a limited number of studies reported the usefulness of serum tumor markers for lung squamous cell carcinoma (SQ). We aimed to examine the significance of serum tumor markers for lung SQ. Methods: Eighty-five lung SQ patients who underwent surgery and followed more than 5-year were included. The ratios of 5-year survivors to all patients in groups with several clinicopathologic factors, including tumor markers, were compared. We also compared the clinicopathologic factors between central type and peripheral type SQ. Results: The majority of patients were male gender and current/ former smokers. Age, pN status, cytokeratin-19 fragment (CYFRA 21-1), squamous cell carcinoma antigen (SCC), and comorbid interstitial pneumonia (IP) were associated with the ratio of 5-year survivors significantly. When patients were compared based on tumor location, high p-stage and CYFRA 21-1 were related to central type SQ. Conclusion: Both SCC and CYFRA 21-1 appeared to be useful prognostic markers for patients with lung SQ. Furthermore, CYFRA 21-1 was related to central type SQ.

卡瑞利珠单抗联合化疗治疗晚期NSCLC疗效及其对血清SCC-Ag、TIMP-1、D-二聚体、miR-206水平的影响

目的探讨卡瑞利珠单抗联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效及其对血清鳞状细胞癌抗原(SCC-Ag)、基质金属蛋白酶组织抑制剂-1(TIMP-1)、D-二聚体(D-D)、微小核糖核酸-206(miR-206)水平的影响。方法选取2022年4月—2023年10月保定市第二中心医院肿瘤科收治的晚期NSCLC患者110例为研究对象,按照随机数字表法分为对照组55例和观察组55例。对照组采用一线化疗方案,观察组在对照组基础上加用卡瑞利珠单抗治疗,21 d为1个周期,共治疗4~6个周期。采用酶联免疫吸附法(ELISA)检测血清SCC-Ag、TIMP-1、D-D水平,实时荧光定量PCR(qPCR)检测miR-206表达水平。比较2组患者临床疗效、治疗前后血清学指标、T淋巴细胞亚群水平及不良反应。结果观察组临床总有效率高于对照组(78.18%vs.60.00%,χ^(2)/P=4.257/0.039);与治疗前比较,治疗4~6个周期后2组血清SCC-Ag、TIMP-1、D-D水平均降低,miR-206表达升高,且观察组各指标降低/升高幅度大于对照组(t/P=38.360/<0.001、4.156/<0.001、9.567/<0.001、4.857/<0.001);与治疗前比较,治疗4~6个周期后2组CD4^(+)T淋巴细胞、CD4^(+)/CD8^(+)升高,CD8^(+)T淋巴细胞降低,且观察组各指标降低/升高幅度大于对照组(t/P=6.241/<0.001、6.879/<0.001、5.631/<0.001);治疗期间,观察组不良反应总发生率低于对照组(5.45%vs.21.82%,χ^(2)/P=6.253/0.012)。结论卡瑞利珠单抗联合化疗治疗晚期NSCLC患者的疗效确切,可有效改善机体免疫功能,降低血清SCC-Ag、TIMP-1、D-二聚体水平,提高miR-206水平。

Partial Trisomy 1q21-qter and Partial Monosomy 7q21-qter Due to a Derivative Chromosome 7 in Myelodysplastic Syndrome Associated with Squamous Cell Carcinoma: Case Report

Background: Myelodysplastic syndromes (MDS) are subtypes of hematological disorders which are known to have partial bone marrow dysplasia, peripheral cytopenia, and later on an increased risk to develop acute myeloid leukemia. Chromosomal aberrations are detected in ~50% of cases of de novo MDS cases and the most common chromosomal abnormalities of this entity include complete or partial monosomy of chromosomes 5 and 7, partial deletion of 20q and 12p, trisomy 8, and 11q23 aberrations. A few primary and/or secondary MDS cases combined with other cancer have been reported. Case Presentation: We report here an adult MDS associated with squamous cell carcinoma (SCC). G-banding and array-proven multicolor banding (aMCB) revealed an unbalanced translocation der(7)t(1;7)(q21;q21), which led to 1q partial trisomy and 7q partial monosomy. Immunophenotype of this case was consistent with refractory anemia with excess of blasts (RAEB-2) according to World Health Organization (WHO) classification. Conclusions: As far as we know, this is the first adult MDS case associated with SCC and an unbalanced translocation t(1;7). Our patient received first cycle of azacitidine treatment and he showed bilateral pleural effusion as a secondary event. This toxicity is not limited to the first cycle as in previous MDS cases;our case is the first one to shown this toxicity as a secondary event of azacitidine treatment. As less than 10 cytogenetcially comparable cases without SCC were reported before in male MDS, we carefully conclude that this cytogenetic aberration may be a hint on a new gender associated MDS subgroup.

Tumour Associated Tissue Eosinophilia as a Prognostic Indicator in Squamous Cell Carcinoma of Upper Aerodigestive Tract

Immune response is known to develop against malignant tumours. Malignant tumours express newer antigen on their cell surface membrane which elicit immunological reaction in and around tumoural tissue. In early part of immune reaction neutrophil, eosinophil migrates followed by monocyte-macrophage cell. Tumor associated tissue eosinophilia (TATE) is believed to play a significant role in the biological behavior of the carcinoma. Eosinophil infiltrate in association with the head and neck squamous cell carcinoma (SCC) have been reviewed from time-to-time. The significance of such an association has been variably thought to be either a potential diagnostic tool for stromal invasion or as a prognostic indicator. The aim of this study was to investigate and evaluate the possible role of the tumour associated tissue eosinophilia (TATE) as a predictive indicator for the grading and establishing prognosis of the upper aerodigestive tract squamous cell carcinoma (SCC).

超声造影结合血清SCC、CYFRA 21-1对食管鳞癌颈部淋巴结转移诊断的价值探讨

目的:探讨超声造影结合血清鳞状细胞癌相关性抗原(serum squamous cell carcinoma asso-ciated antigen,SCC)、细胞角蛋白19片段21-1(cytokeratin 19 fragment 21-1,CYFRA 21-1)在食管鳞癌颈部淋巴结转移诊断中的应用价值。方法:选取2020年4月至2023年8月收治的164例食管鳞癌患者,根据术后病理学检查分为转移组(n=58)和未转移组(n=106)。所有患者术前均行超声造影检查及血清SCC、CYFRA 21-1水平检测。比较两组的超声造影参数(峰值强度(peak inten-sity,PI)、达峰时间(time to peak,TTP)、平均通过时间(mean transit time,MTT))和血清标志物水平,并通过ROC曲线分析诊断价值。结果:转移组PI、MTT及血清SCC、CYFRA 21-1水平显著高于未转移组(P<0.05),而TTP显著低于未转移组(P<0.05)。超声造影三项参数联合诊断的灵敏度、特异度和AUC分别为79.31%、81.13%和0.821;与血清标志物联合后,灵敏度提升至96.55%,AUC提升至0.913(P<0.05)。结论:超声造影结合血清SCC、CYFRA 21-1能够显著提高食管鳞癌颈部淋巴结转移的诊断效能,为临床个体化治疗方案的制定提供依据。

宫颈癌患者血清SCC-Ag、NLR水平与临床病理特征及预后关系

目的:探讨宫颈癌患者血清鳞状细胞癌抗原(SCC-Ag)、中性粒细胞与淋巴细胞比值(NLR)与临床病理特征及预后关系。方法:纳入2018年1月-2023年1月本院收治的108例宫颈癌患者为宫颈癌组,宫颈上皮内瘤病变(CIN)患者108例为CIN组,健康体检健康女性108例为对照组。比较3组血清SCC-Ag、NLR水平,分析宫颈癌组血清SCC-Ag、NLR水平与临床病理特征及与预后关系。结果:血清SCC-Ag、NLR水平,宫颈癌组(7.35±1.76、4.65±1.06)、CIN组(2.06±0.53、3.41±0.89)、对照组(0.54±0.12、1.53±0.34)依次降低(P<0.05)。宫颈癌患者血清SCC-Ag、NLR水平与病理类型、FIGO分期、病理分级、肌层浸润深度和盆腔淋巴结转移有关(P<0.05)。Kaplan-Meier显示,SCC-Ag、NLR高表达组总生存率、无病生存率均低于SCC-Ag、NLR低表达组,SCC-Ag高表达+NLR高表达组总生存率、无病生存率最低(均P<0.05)。结论:宫颈癌患者血清SCC-Ag、NLR水平与病理类型、FIGO分期、病理分级和肌层浸润深度等有关,且SCC-Ag、NLR水平越高患者预后越差。

术后血清MMP-2、SCCA1表达水平对鼻腔鼻窦内翻性乳头状瘤术后复发的预测价值

目的探讨术后血清基质金属蛋白酶-2(MMP-2)、鳞状细胞癌抗原1(SCCA1)表达水平对鼻腔鼻窦内翻性乳头状瘤(SNIP)患者术后复发的预测价值。方法回顾性分析手术治疗的SNIP患者65例,根据术后2年内复发情况,将其分为复发组(n=12)和未复发组(n=53)。Elisa法检测手术前后血清MMP-2、SCCA1表达水平。收录临床资料,包括性别、年龄、饮酒史、吸烟史、肿瘤部位、手术方式、术后有无应用5-氟尿嘧啶(5-Fluorouracil,5-FU)、Krouse分期及有无糖尿病、高血压;Logistic回归分析影响SNIP患者术后复发的危险因素;ROC曲线分析术后血清MMP-2、SCCA1表达水平对SNIP患者术后复发的预测价值。结果术后,2组血清MMP-2、SCCA1表达水平均较术前降低(P<0.05),但复发组血清MMP-2、SCCA1表达水平均高于未复发组(P<0.05)。Logistic回归分析显示,有吸烟史、术后未应用5-FU、Krouse分期为T3~T4期、术后血清MMP-2表达水平、SCCA1表达水平是影响SNIP患者术后复发的危险因素(P<0.05)。ROC曲线分析显示,术后血清MMP-2、SCCA1表达水平单独及二者联合预测SNIP患者术后复发的曲线下面积(AUC)分别为0.786、0.800、0.836,敏感度分别为83.33%、75.00%、91.67%,特异度分别为71.70%、79.25%、75.47%。结论术后血清MMP-2、SCCA1表达水平可作为预测SNIP患者术后复发的辅助指标,且二者联合预测的效果更佳。

肺癌患者血清CA724、CA153、SCC水平与病理特征及术后复发转移的关系

目的探讨肺癌(LC)患者血清糖类抗原724(CA724)、糖类抗原153(CA153)、鳞癌抗原(SCC)水平与病理特征及术后复发转移的关系。方法选取2019年6月至2020年12月在周口市中心医院接受手术治疗的102例LC患者,根据其2 a后是否存在复发转移分为复发转移组和未复发转移组,比较两组术前血清CA724、CA153和SCC水平及病理特征,分析影响术后复发转移的因素。结果随访后,102例患者中有65例发生复发转移,发生率为63.73%;复发转移组CA724、CA153和SCC水平均高于未复发转移组(P<0.05);腺癌组CA724水平高于小细胞肺癌组和鳞癌组(P<0.05),3组CA153水平差异无统计学意义(P>0.05);鳞癌组SCC水平高于小细胞肺癌组和腺癌组(P<0.05)。Ⅱ期和Ⅲ期CA724、CA153和SCC水平高于Ⅰ期(P<0.05)。复发转移组和未复发转移组TNM分期和分化程度差异有统计学意义(P<0.05)。Cox单因素回归分析结果显示,TNM分期、高水平CA724、CA153、SCC和分化程度是LC患者术后复发转移的影响因素(P<0.05);多因素回归分析结果显示,TNM分期为Ⅲ期和高水平的CA724、CA153和SCC均为影响LC患者术后复发转移的独立危险因素(P<0.05)。结论LC患者血清CA724、CA153、SCC表达水平与LC病理特征和术后复发转移关系密切,临床可通过检测血清CA724、CA153、SCC水平来评估术后复发转移情况。

CYFRA21-1、CA199、SCC、CRP联合检测在肺癌诊断中的应用价值

目的分析诊断肺癌中糖类抗原199(CA199)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、C反应蛋白(CRP)、鳞状细胞癌抗原(SCC)联合检测的价值。方法选取30例肺癌患者作为肺癌组,并纳入50例健康体检者作为健康组。两组均进行CYFRA21-1、SCC、CRP、CA199检查。对比两组CA199、CYFRA21-1、SCC、CRP水平;对比CA199、CYFRA21-1、SCC、CRP单独检测与联合检测对肺癌的诊断效能。结果肺癌组CA199(9.31±0.19)U/ml、CRP(23.49±1.36)mg/L、CYFRA21-1(4.43±0.09)ng/ml、SCC(29.50±0.16)ng/ml明显高于健康组的(3.27±0.11)U/ml、(5.48±1.15)mg/L、(1.20±0.16)ng/ml、(0.56±0.04)ng/ml,差异具有统计学意义(P<0.05)。CA199单独检测的诊断准确度、灵敏度和特异度分别为67.50%、46.67%、80.00%,CRP分别为73.75%、60.00%、82.00%,SCC分别为63.75%、40.00%、78.00%,CYFRA21-1分别为76.25%、66.67%、82.00%,联合检测分别为87.50%、90.00%、86.00%;CA199、CYFRA21-1、SCC、CRP联合检测的诊断准确度、特异度和灵敏度均高于单独检测。结论CA199、CYFRA21-1、SCC、CRP对肺癌诊断具有重要参考价值,通过联合检测能提高诊断特异度、准确度、敏感度。

急性支气管炎患儿血清骨膜蛋白、SCCA表达及临床意义分析

目的检测急性支气管炎患儿血清骨膜蛋白、鳞状上皮细胞癌抗原(SCCA)水平,并探讨二者表达的临床意义。方法回顾性选取2018年10月至2020年4月于山东第二医科大学附属医院住院并接受治疗的78例急性支气管炎患儿为研究对象,纳入支气管炎组,根据疾病严重程度分为轻度52例和重度26例。选取同期健康体检的儿童86名作为对照组。检测并比较支气管炎组与对照组的骨膜蛋白、SCCA水平。比较轻度和重度急性支气管炎患儿的炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]、肺功能指标[第1秒用力呼气量(FEV1)、FEV1/用力肺活量(FVC)、最大呼气中段流量(MMEF)、最大呼气峰流速(PEF)]水平。采用Pearson法分析重度急性支气管炎患儿血清骨膜蛋白、SCCA水平与炎症因子水平、肺功能指标的相关性;以多因素Logistic回归分析对影响急性支气管炎加重的因素进行分析。结果支气管炎组患儿的血清骨膜蛋白、SCCA水平分别为(409.37±98.24)ng/L、(1.42±0.43)ng/mL,均明显高于对照组[(264.31±82.54)ng/L、(0.95±0.31)ng/mL],差异均有统计学意义(P<0.05)。重度急性支气管炎患儿的血清骨膜蛋白、SCCA、IL-6、TNF-α、hs-CRP水平分别为(524.46±123.94)ng/L、(1.82±0.52)ng/mL、(16.62±4.18)ng/L、(17.62±5.21)ng/L、(18.46±6.02)mg/L,均明显高于轻度急性支气管炎患儿[(348.92±64.28)ng/L、(1.22±0.24)ng/mL、(4.62±1.38)ng/L、(3.83±1.09)ng/L、(9.34±0.71)mg/L],FEV1、FEV1/FVC、MMEF、PEF水平分别为(2.06±0.27)V/L、56.62±6.26、(1.47±0.36)L/s、(4.33±0.62)L/s,均明显低于轻度急性支气管炎患儿[(3.12±0.46)V/L、67.38±6.14、(2.36±0.43)L/s、(5.64±0.71)L/s],差异均有统计学意义(P<0.05)。重度急性支气管炎患儿血清骨膜蛋白、SCCA水平与炎症因子均呈正相关(P<0.05),与肺功能指标均呈负相关(P<0.05)。骨膜蛋白、SCCA是影响急性支气管炎加重的独立危险因素(P<0.05)。结论急性支气管炎患儿血清骨膜蛋白、SCCA水平均显著升高,且随病情加重,血清骨膜蛋白、SCCA水平进一步升高,在急性支气管炎的病情评估中可能有重要作用。

血清CEA、NSE、SCC-Ag和CA125联合检验在非小细胞肺癌中的诊断价值

目的探究血清癌胚抗原(CEA)、神经特异性烯醇化酶(NSE)、鳞癌相关抗原(SCC-Ag)、糖类抗原125(CA125)联合检验在非小细胞肺癌(NSCLC)中的诊断价值。方法选取2021年1月至2024年1月在本院就诊的110例NSCLC患者作为NSCLC组,另选取同期在本院体检的健康志愿者50例作为对照组。比较2组血清CEA、NSE、SCC-Ag以及CA125水平的差异;依据病理T分期将NSCLC组患者分为T1期、T2期、T3期3个不同亚组,依据病理N分期将NSCLC患者分为N0期、N1期、N2期3个不同亚组,比较不同病理T分期、N分期NSCLC患者血清CEA、NSE、SCC-Ag以及CA125水平的差异;并绘制ROC曲线分析上述指标单一及联合在NSCLC诊断中的效能。结果在CEA、NSE、SCC-Ag、CA125水平比较上,NSCLC组均高于对照组(P<0.05)。血清CEA、NSE、SCC-Ag、CA125水平均随NSCLC患者病理T分期的递增而升高(P<0.05),且各分期结果比较差异有统计学意义(P<0.05)。血清CEA、NSE、SCC-Ag、CA125水平均随NSCLC患者病理N分期的递增而升高(P<0.05),且各分期结果比较差异有统计学意义(P<0.05)。CEA、NSE、SCC-Ag、CA125诊断NSCLC的AUC分别为0.869(95%CI为0.827~0.917)、0.873(95%CI为0.812~0.921)、0.854(95%CI为0.789~0.905)、0.826(95%CI为0.758~0.881),4者联合诊断NSCLC的AUC为0.982(95%CI为0.947~0.996),均较CEA、NSE、SCC-Ag、CA125各单一指标效能更高(Z=4.152、4.268、4.663、4.783,P<0.001)。结论血清CEA、NSE、SCC-Ag、CA125与NSCLC病理类型、淋巴结转移数目、EGFR基因型等存在关系,且通过联合检测CEA、NSE、SCC-Ag、CA125水平可有效提高临床诊断NSCLC的效能。

紫杉醇脂质体联合顺铂化疗对中晚期宫颈癌患者疗效及对FGFR4、SCCA水平的影响研究

目的探讨紫杉醇脂质体联合顺铂化疗对中晚期宫颈癌患者疗效及对FGFR4、SCCA水平的影响。方法选取2020年5月至2021年10月我院收治的中晚期宫颈癌患者93例,根据不同治疗方案分为观察组(n=48)和对照组(n=45),对照组采用顺铂化疗,观察组采用紫杉醇脂质体联合顺铂化疗。从入院当日开始,21天为1个疗程,治疗2个疗程。比较入院当日及治疗后治疗有效率、血清成纤维细胞生长因子受体(FGFR4)、鳞状细胞癌抗原(SCCA)、血管内皮生长因子(VEGF)水平及不良反应发生率。结果观察组血清FGFR4、SCCA、VEGF水平、不良反应发生率均显著低于对照组,治疗有效率高于对照组,差异有统计学意义(P值均<0.05)。结论紫杉醇脂质体联合顺铂化疗能够有效破坏肿瘤细胞遗传物质及新生血管,抑制肿瘤细胞增殖分化,并诱导其凋亡,从而延缓肿瘤发展进程,提升治疗有效率。

CEA、SCC、CA724在食管癌患者血清中的表达及临床意义

目的探讨癌胚抗原(CEA)、鳞状细胞癌抗原(SCC)、糖类抗原724(CA724)在食管癌(EC)患者血清中的表达及临床意义。方法选择105例拟行手术治疗的EC患者纳入观察组,另选取同期105例健康体检者为对照组,检测2组血清CEA、SCC、CA724表达水平,分析血清CEA、SCC、CA724与食管癌患者临床特征的关系。术后进行1年随访,统计患者预后情况,分析上述指标联合检测对EC患者预后的预测价值。结果观察组血清CEA、SCC、CA724水平高于对照组(P<0.05)。EC患者血清CEA、SCC、CA724水平与临床分期、分化程度、肿瘤直径、淋巴结转移有关(P<0.05)。105例EC患者均完成1年随访,其中预后不良38例,血清CEA、SCC、CA724联合预测EC患者预后情况的AUC均>0.7。结论EC患者血清中CEA、SCC、CA724水平较高,且联合检测对EC患者预后情况具有较高的预测价值。

血清HE4、SCC-Ag联合TCT检查诊断宫颈癌价值

目的:探讨血清人附睾上皮分泌蛋白4(HE4)、鳞状细胞癌相关抗原(SCC-Ag)联合宫颈薄层液基细胞学检测(TCT)诊断宫颈癌(CC)价值。方法:收集2021年10月-2023年7月本院病理确诊CC患者40例(CC组)、宫颈良性病变(CBL组,包括宫颈炎、宫颈上皮内瘤变)患者228例为CBL组。对比两组血清HE4、SCC-Ag水平,两组HE4、SCC-Ag、TCT检测CL阳性检出率;根据病理结果分析血清HE4、SCC-Ag水平、TCT诊断CL价值。结果:CC组血清HE4(188.71±39.15 pmol/L)、SCC-Ag(1.81±0.21 ng/ml)水平高于CBL组(73.65±11.52 pmol/L、0.64±0.12 ng/ml)(P<0.05)。TCT、HE4、SCC-Ag诊断CC的灵敏度(82.5%、72.5%、75.0%),特异度(77.6%、87.7%、86.8%),准确度(78.4%、85.5%、85.1%),3项指标联合诊断CC的灵敏度70.0%、特异度93.9%、准确度90.3%,联合检测准确度高于各单独指标检测(P<0.05)。结论:CC患者血清HE4、SCC-Ag水平及TCT检测阳性率均高于CBL患者,3项指标联合诊断准确度提高。